Accure Therapeutics
"Accure Therapeutics, a private pharma R&D engine at clinical stage in the CNS field, was launched in 2020 with a Series A funding led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development (CDTI)."
"The company develops a drug candidate portfolio in three programs (ACT-01, ACT-02, ACT-03) pursuing innovative targets that focus on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy."
"Accure Therapeutics follows a straightforward corporate model, consisting of integrating valuable assets, people, R&D programs and investors to address the need for disease modifier medicines to treat CNS diseases. The current portfolio serves as the basis for further expansion towards more R&D programs and targeted indications."
Latest Accure Therapeutics News & Features
8 December 2022
26 May 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze